Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stereotactic Radiotherapy for Oligo-residual Intracranial Disease in EGFR-mutated NSCLC
NCT06020066Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Fudan University. Primary endpoint: Progression-free survival at 2 years. Started Aug 2023; status: active, not recruiting.
Beyond the preview
Go deeper on NCT06020066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020066.